- This event has passed.
BioForum: From Hospital Beds to Healthy Lives: The Impact of Innovative Medicines
June 28, 2023 @ 5:00 pm - 7:00 pm AEST
Event Navigation
In Australia, important decisions are being made which medicines are approved and available on the Pharmaceutical Benefits Scheme, improving both access and affordability for patients.Join American economist and Columbia University Professor Frank Lichtenberg who will present key findings from his report: The Effect of New Medicines Provided by the Pharmaceutical Benefits Scheme (PBS) on Mortality and Hospital Utilisation in Australia, 2002 – 2019.Professor Lichtenberg will also discuss the health and economic benefits of adding more medicines to the PBS for patients and hospitals, and participate in a panel Q&A facilitated by Paul Cross, Founder and Managing Director of Daily Dispatch to explore the impact of those findings. They will be joined by Anne-Maree Englund, Head of Strategic Policy Implementation, Medicines Australia, Deidre Mackechnie, Executive Officer, Australian Patient Advocacy Alliance, and James McDonnell, CSL Vifor, General Manager Australia and New Zealand, Board Member Medicines Australia, who will also discuss the national Health Technology Assessment (HTA) Policy and Methods Review to improve access to new health technologies.
Event details:
Date: Wednesday 28 June 2023
Time (AEST):
4:45 pm Guest arrival
5:00 pm: Presentation (summary of findings) and interview
5:20 pm – 6:00 pm: Panel and Q&A
6:00 pm – 7:00 pm: Networking (in person only)
Format: Hybrid – In person and online
Venue: Swinburne Studio, ACMI, Federation Square, Corner Flinders and Swanston Streets, Melbourne VIC 3000
Speakers:
Professor Frank Lichtenberg – Cain Brothers & Company Professor of Healthcare Management
Deidre Mackechnie – Executive Officer, Australian Patient Advocacy Alliance
Anne-Maree Englund – Head of Strategic Policy Implementation, Medicines Australia
James McDonnell, CSL Vifor, General Manager Australia and New Zealand, Board Member Medicines Australia
Facilitator: Paul Cross, Managing Director, Daily Dispatch
Host: Jeff Malone, CEO, BioMelbourne Network
Registration:
In-person: Members $85; Non Members $175
Online: Members $25; Non Members $45
Unsure if your organisation is a member? Check our member directory
This event is sponsored by the State Government of Victoria
In collaboration with Medicines Australia
Cancellation Policy
In-person registration:
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
Online registration:
Full refund given up to 3 days prior to the event
No refunds within 3 days of the event
Professor Frank R. Lichtenberg, Cain Brothers & Company Professor of Healthcare Management
Frank R. Lichtenberg is Cain Brothers & Company Professor of Healthcare Management in the Faculty of Business Economics at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.
Professor Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Department. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organisations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.
Professor Lichtenberg was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research!America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.
He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organisations. He has served as a consultant to private organisations and government agencies, including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council.
Professor Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Department. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organisations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.
Professor Lichtenberg was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research!America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.
He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organisations. He has served as a consultant to private organisations and government agencies, including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council.
Paul Cross, Managing Director, Daily Dispatch
Paul Cross is the founder of Daily Dispatch, the publisher of PharmaDispatch, BiotechDispatch and HealthDispatch, online journals focused on providing news and analysis concerning the Australian pharmaceutical, biotechnology and private health sectors. He has over 15 years’ experience in health care, having served in senior roles in government and the private sector.
Anne-Maree Englund, Head of Strategic Policy Implementation, Medicines Australia
Anne-Maree Englund is passionate about the potential of innovative technologies to improve health outcomes. She has over 20 years’ experience in the biopharmaceutical and medical technology industries. An engineer by trade, Anne-Maree started her career at the medical device innovator Cochlear, with roles in manufacturing and quality management, including four years in Switzerland and Belgium.
She has been General Manager of Operations at health IT startup Humanetix, seeing the company through a successful clinical trial of their unique software. After completing a master’s degree in public policy, Anne-Maree worked as Policy Manager at pharmaceutical company MSD. She is currently Head of Strategic Policy Implementation at Medicines Australia, a role which perfectly combines her interests in medical innovation and health policy.
She has been General Manager of Operations at health IT startup Humanetix, seeing the company through a successful clinical trial of their unique software. After completing a master’s degree in public policy, Anne-Maree worked as Policy Manager at pharmaceutical company MSD. She is currently Head of Strategic Policy Implementation at Medicines Australia, a role which perfectly combines her interests in medical innovation and health policy.
Deidre Mackechnie, Executive Officer, Australian Patient Advocacy Alliance
With a passion for the importance of the patient voice in federal policy, Deidre has held several senior management and executive roles within the public health sector, as well as gaining invaluable experience in the not-for-profit space as former CEO of Multiple Sclerosis Australia.
In addition to her work at the APAA, Deidre is also the board chair of St Kilda Mums, a Victorian based charity focused on rehoming pre-loved nursery goods to provide babies with a safe start in life.
In addition to her work at the APAA, Deidre is also the board chair of St Kilda Mums, a Victorian based charity focused on rehoming pre-loved nursery goods to provide babies with a safe start in life.
James McDonnell, CSL Vifor, General Manager Australia and New Zealand, Board Member Medicines Australia
James McDonnell is a senior biopharmaceutical executive with over 30 years’ experience including the invaluable knowledge of establishing two original Australian affiliates with full profit and loss responsibility. A proven track record of success which can be attributed to building exceptional partnerships, creating a patient-centered focus, developing positive cultures whilst maintaining a high level of determination. His drive and resilience have enabled him to be agile to the needs of the businesses and continuing to drive a high performance culture with a clear purpose and vision.
James is a pharmacist and holds a GAICD from the Australian Institute of Company Directors. James has been an employee with CSL Vifor for 13 years in Australia and has held the role of General Manager throughout that period. James established the affiliate as employee number 1 and guided its growth in employees and a network of partners. James is currently a member of the Board of Medicines Australia.
James is a pharmacist and holds a GAICD from the Australian Institute of Company Directors. James has been an employee with CSL Vifor for 13 years in Australia and has held the role of General Manager throughout that period. James established the affiliate as employee number 1 and guided its growth in employees and a network of partners. James is currently a member of the Board of Medicines Australia.
Related Events
